Masked Hypertension Clinical Trial
Official title:
Antihypertensive Treatment in Masked Hypertension for Target Organ Protection(ANTI-MASK)
The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria). Improvement was defined as the relevant parameter back to normal or declined at least 20%. The secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02804074 -
MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement
|
N/A | |
Active, not recruiting |
NCT02503943 -
Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
|
Phase 4 | |
Recruiting |
NCT02156024 -
The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension
|
Phase 4 | |
Completed |
NCT02142881 -
Treatment of Masked Hypertension
|
Phase 3 | |
Active, not recruiting |
NCT04200716 -
Arterial Function After Two Different Physical Exercise Intensities in Prehypertension
|
N/A | |
Not yet recruiting |
NCT05409898 -
Screening for Masked Hypertension With Smart Wearable Devices (SMART)
|
||
Withdrawn |
NCT04121299 -
Mechanism of Masked Hypertension - Intervention
|
Phase 3 | |
Recruiting |
NCT02663336 -
Prevalence of Masked Hypertension in Nephrological Patients
|
||
Completed |
NCT04251975 -
Masked Hypertensive Patients With Obstructive Sleep Apnea
|
N/A |